Instrument Inactif

Autres langues ImmunoGen, Inc.

Actions

IMGN

US45253H1014

Recherche biotechnologique et médicale

Autres langues

20/02/24	AbbVie CEO to Retire; COO Robert Michael Named Successor
13/02/24	BioPharma Credit gets USD50.6 million from Abbvie's ImmunoGen purchase
13/02/24	Biopharma Credit Secures $51 Million Loan Repayment from US Biotech ImmunoGen
13/02/24	ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from S&P Global BMI Index
13/02/24	ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from S&P TMI Index
13/02/24	ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from S&P Biotechnology Select Industry Index
12/02/24	Top Stories at Midday: Bezos Sells Nearly 12 Million Amazon Shares; Diamondback's $26 Billion Endeavor Energy Deal; Citigroup's Risk Management Procedures Rebuked; AbbVie Buys ImmunoGen
12/02/24	AbbVie Completes $10.1 Billion Acquisition of ImmunoGen, Lowers Q1 Adjusted EPS Guidance
12/02/24	AbbVie Acquires ImmunoGen for $31.26 per Share
12/02/24	Immunogen, Inc. Announces Board Changes
12/02/24	AbbVie Completes Acquisition of ImmunoGen
12/02/24	ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index
12/02/24	AbbVie Inc. completed the acquisition of ImmunoGen, Inc. from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc., State Street Corporation, The Vanguard Group, Inc. and others.
09/02/24	ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Biotechnology Index
07/02/24	ImmunoGen Insider Sold Shares Worth $352,391, According to a Recent SEC Filing
07/02/24	ImmunoGen Insider Sold Shares Worth $588,733, According to a Recent SEC Filing
02/02/24	AbbVie 4Q Sales Lower as Himura Revenue Sinks
02/02/24	Omzetdaling Abbvie valt mee
02/02/24	AbbVie raises 2027 sales forecast for new immunology drugs to $27 billion
02/02/24	AbbVie profit beats estimates as Humira, Botox sales weather hit from rivals
01/02/24	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22/01/24	HBM bleibt nach neun Monaten in den roten Zahlen
19/01/24	Immunogen Insider Sold Shares Worth $5,562,450, According to a Recent SEC Filing
08/01/24	Drugmakers kick off industry conference with two cancer deals
08/01/24	J&J to buy cancer therapy developer Ambrx for $2 bln